Proteome Sciences plc (AIM:PRM)
London · Delayed Price · Currency is GBP · Price in GBX 1.900
+0.100 (5.56%)
Jul 27, 2026, 5:15 PM GMT
Proteome Sciences Balance Sheet
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.78 | 1.13 | 2.03 | 3.99 | 2.39 |
Cash & Short-Term Investments | 0.78 | 1.13 | 2.03 | 3.99 | 2.39 |
Cash Growth | -30.76% | -44.35% | -49.25% | 67.32% | 8.01% |
Accounts Receivable | 0.62 | 0.43 | 0.96 | 1.44 | 0.6 |
Other Receivables | 0.13 | 0.3 | 0.35 | 0.56 | 0.48 |
Total Trade Receivables | 0.75 | 0.73 | 1.3 | 2 | 1.08 |
Inventory | 0.54 | 0.73 | 0.84 | 0.9 | 1.09 |
Total Current Assets | 2.07 | 2.59 | 4.16 | 6.9 | 4.56 |
Net Property, Plant & Equipment | 1.97 | 2.4 | 3.08 | 1.32 | 1.27 |
Goodwill | 4.22 | 4.22 | 4.22 | 4.22 | 4.22 |
Total Assets | 8.26 | 9.21 | 11.46 | 12.43 | 10.05 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.62 | 0.78 | 0.63 | 0.82 | 0.6 |
Short-Term Debt | 14.46 | 12.63 | 11.24 | 11.26 | 10.83 |
Current Portion of Leases | 0.49 | 0.6 | 0.61 | 0.3 | 0.26 |
Unearned Revenue | - | - | 0 | 0.1 | 0.04 |
Total Current Liabilities | 16.57 | 14.01 | 12.47 | 12.49 | 11.72 |
Long-Term Debt | - | 0.25 | - | - | - |
Long-Term Leases | 0.82 | 1.04 | 1.63 | 0.35 | 0.6 |
Other Long-Term Liabilities | 0.39 | 0.42 | 0.42 | 0.43 | 0.5 |
Total Long-Term Liabilities | 1.22 | 1.71 | 2.05 | 0.79 | 1.1 |
Total Liabilities | 17.79 | 15.72 | 14.52 | 13.28 | 12.82 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 2.95 | 2.95 | 2.95 | 2.95 | 2.95 |
Additional Paid-in Capital | 66.99 | 66.97 | 66.93 | 66.72 | 66.41 |
Accumulated Other Comprehensive Income | 0.04 | -0.09 | -0.01 | 0.03 | -0.13 |
Retained Earnings | -79.51 | -76.35 | -72.94 | -70.54 | -72.01 |
Shareholders' Equity | -9.53 | -6.52 | -3.07 | -0.84 | -2.78 |
Total Liabilities & Equity | 8.26 | 9.21 | 11.46 | 12.43 | 10.05 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 15.77 | 14.52 | 13.48 | 11.92 | 11.69 |
Net Cash (Debt) | -14.99 | -13.39 | -11.45 | -7.92 | -9.3 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -0.05 | -0.04 | -0.04 | -0.03 | -0.03 |
Book Value | -9.53 | -6.52 | -3.07 | -0.84 | -2.78 |
Book Value Per Share | -0.03 | -0.02 | -0.01 | -0.00 | -0.01 |
Tangible Book Value | -13.75 | -10.73 | -7.28 | -5.06 | -6.99 |
Tangible Book Value Per Share | -0.05 | -0.03 | -0.02 | -0.02 | -0.02 |